Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919249 | 0.91 | SLC10A2 (0.61) | SLC10A2 | |
| SCHEMBL2938620 | 0.86 | SLC10A2 (0.81) | SLC10A2 | |
| SCHEMBL14559686 | 0.78 | NR1H4 (0.48) | SLC10A2 | |
| SCHEMBL8200633 | 0.78 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL2843089 | 0.78 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL25274089 | 0.78 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL1362560 | 0.78 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL1362558 | 0.78 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL29429783 | 0.78 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL5744361 | 0.77 | NR1H4 (0.63) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427713-B1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ALBIREO AB (SE) | 2010-01-06 | — | — | EP | claimed |
| US-7125864-B2 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | claimed |
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ALBIREO AB (SE) | 2005-02-10 | — | — | US | claimed |
| US-7893048-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7863265-B2 | 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-7842684-B2 | 2-azetidinone derivatives such as N-({4-[(2R,3R)-3-{[(2R)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine, used for the treatment of hyperlipemia | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20100137273-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-7125864-B2 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-20060199797-A1 | Use of an ibat inhibitor for the treatment of prophylaxis of constipation | ALBIREO AB (SE) | 2006-09-07 | — | — | US | disclosed |
| US-20060083790-A1 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | ALBIREO AB (SE) | 2006-04-20 | — | — | US | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ALBIREO AB (SE) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | CYP46A1, CYP51A1, NPC1L1 | SLC10A2 139/4885 |
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | SLC10A2, SLC10A1, LCAT | SLC10A2 1/4885 |
| US-20100137273-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | SLC10A2 51/4885 |
| US-20060083790-A1 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | SLC10A2, SI, SLC6A1 | SLC10A2 1/4885 |
| US-20060199797-A1 | Use of an ibat inhibitor for the treatment of prophylaxis of constipation | SLC10A2, GABRQ, SLC6A1 | SLC10A2 1/4885 |
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | CYP46A1, NPC1L1, LIPA | SLC10A2 77/4885 |
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | SLC10A2 60/4885 |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | NPC1L1, CYP46A1, PCSK9 | SLC10A2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.